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 Pancreatic ductal adenocarcinoma (PDAC) is a genetic disease that evolves from 
precursor lesions, the most common of which are pancreatic intraepithelial neoplasia (PanINs).  
In this study, we present RNA-sequencing analysis of PanINs.  We identify genes subject to 
differential expression between PanIN and normal pancreatic duct and between low-grade and 
high-grade PanIN. One novel gene identified as overexpressed in PanIN and invasive pancreatic 
ductal adenocarcinoma is interleukin-2 receptor subunit gamma (IL2RG) which encodes the 
common gamma chain.  CRISPR-mediated depletion of IL2RG in orthotopically implanted 
pancreatic cancer cells resulted in attenuated tumor growth in mice.  Additionally, we examine 
the therapeutic sensitivities of inactivation of Ataxia Telangiectasia Mutated (ATM), a critical 
DNA repair gene not infrequently mutated in pancreatic cancers.  We find that ATM-depleted 
pancreatic cancer cell lines have no added sensitivity to several chemotherapeutic agents, but are 
markedly sensitive to radiotherapy.  These data contribute new considerations for existing 
therapeutic candidates and open the door to a new set of potentially-targetable pathways for 
disease management. 
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Pancreatic cancer: the present overview 
 Pancreatic cancer is the third-leading cause of cancer death in the USA, with a 5-
year survival rate of 8%1.  Surgical resection remains the best treatment option for pancreatic 
cancer2, 3, however, less than 20% of patients are diagnosed with resectable cancers.  Although 
PanINs, the most common precursor lesion, are thought to exist in a treatable, pre-symptomatic 
state for years or decades prior to becoming invasive, no non-invasive screening test exists to 
detect them.  Instead, cancers are almost universally diagnosed at an invasive stage unamenable 
to therapy.  Surgery is the only curative treatment option for pancreatic cancer, but it is not 
possible in most cases.  However, pancreatic resection with curative intent does not remove the 
cancer completely in many cases due to microscopically positive margins4 and/or the presence of 
micrometastases5, underlining a need for adjuvant therapy.  Recurrence of pancreatic cancer is 
common, and 5-year survival after pancreatic resection is only ~ 20%6. Systemic chemotherapy 
can be used to downstage advanced cancers or reduce the chance of post-operative recurrence7, 
but current options confer limited benefit and have high toxicities8.  Many novel therapies have 
been evaluated for pancreatic cancer and most of these have failed to show benefit. The role of 
adjuvant vs. neoadjuvant therapy and the role of radiotherapy is still not clear and requires further 
study9-11. Thus, the high mortality rate of pancreatic cancer is largely owed to two factors:  an 
inability to detect early, low-stage cancer and pre-invasive lesions, and a paucity of effective 
cancer therapy. Examination of the molecular aberrations characterizing PanINs and PDAC has 
the potential to reveal targets for early detection and treatment and to better understand the 
biology of the disease.  In chapter 2, we present the results of RNA sequencing analysis from 
PanIN samples and identify IL2RG as a novel overexpressed gene in pancreatic cancer.  In 
chapter 3 we describe the use of bioinformatics tools to identify novel transcripts in PanINs. In 




Mutated that occurs in a subset of cancers and show evidence for their exquisite sensitivity to 
fractionated radiotherapy. 
 
Genetic alterations in Pancreatic ductal adenocarcinoma 
 The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma 
(PDAC), which accounts for >85% of cases 12.  The acquired genetic abnormalities of PDAC are 
extensive and well-understood.  The four most commonly mutated genes are KRAS13, CDKN2A14, 
TP5315, and SMAD4/DPC416.  Comprehensive genetic analysis of PDAC found tumors to contain 
genetic alterations falling into core signaling pathways that were individually altered in 67 to 
100% of cases17.  Many of these pathways are unsurprising: perturbation of KRAS signaling, Wnt 
signaling, and Hedgehog signaling promote proliferation, while disruption of DNA damage 
control, chromatin regulation, and apoptosis pathways support an accumulation of mutations and 
resistance to cell death from their detection.  Others relate to additional growth signaling, 
disruption of the native microenvironment, and invasion.  In all, these core pathways illustrate a 
roadmap of the changes necessary for PDAC to achieve expansion, invasion, and metastasis as 
well as potential targets for screening and therapy. 
 
Precursors to PDAC 
PDAC is understood to arise from the stepwise progression of one of three precursor 
lesions: pancreatic intraepithelial neoplasia (PanINs), intraductal papillary neoplasms (IPMNs), 
and mucinous cystic neoplasms (MCNs) 18.  PanINs are thought to be the precursors to an 
overwhelming majority of PDAC and are distinct from the other two precursors in being 




thought be to be common in adults, few of these lesions ever progress to PanIN-3 (carcinoma in 
situ), with one estimate from Terhune et al suggesting the proportion to be as low as 1%.19  
Between the complications that can arise from pancreatic surgery, the lack of a non-invasive 
screen for PanINs, and the low risk of progression of PanIN-1, much energy has been put into 
identifying risk factors for developing PanIN and to understand the molecular progression of 
PanIN. 
Known risk factors for pancreatic cancer include a host of inherited germline mutations 
in BRCA220, p1621, ATM22, STK1123, PRSS124, and PALB225.    Chronic pancreatitis is a key risk 
factor for pancreatic cancer26.   Germline mutations in PRSS1 predispose patients to developing 
recurrent acute pancreatitis at a young age so that carriers have a lifetime risk of pancreatic cancer 
of ~30%. Heterozygous carriers of mutations in the pancreatitis risk genes, CFTR and SPINK124,, 
are at increased risk of developing chronic pancreatitis but these are considered modifier genes as 
most carriers will not develop pancreatitis or pancreatic cancer 27.   In mouse models, cerulein-
induced pancreatitis accelerates the development of PanINs 28, 29.  The PanScan Project, a multi-
stage genome wide association study undertaken by the Pancreatic Cancer Cohort Consortium, 
has identified single nucleotide polymorphisms associated with increased risk of pancreatic 
cancer in multiple loci including ABO, TERT, PDX-1 30and nuclear receptor subfamily 531.  
Environmental and lifestyle factors also play a role in pancreatic cancer development.  
Comprehensive meta-analyses have established an elevated relative risk for pancreatic cancer 
associated with obesity32 33.  Many studies have also linked diabetes mellitus34-37 and smoking37-39 
to pancreatic cancer.   Smoking has been found to double the average risk of developing 
pancreatic cancer, and pancreatic cancers in smokers have a higher mutational burden than those 
in nonsmokers40.  These factors, in isolation or combination, contribute to the risk of developing 
PDAC. 




 In a progression model established by Hruban et al42, 3 grades of PanINs can be 
distinguished histologically.  PanIN-1s have a flat or micropapillary architecture, with tall 
columnar cells and an accumulation of intracellular mucin.  PanIN-2s are papillary and display 
mild cytological atypia: nuclear crowding, depolarization, and hyperchromasia.  PanIN-3s display 
a dramatic breakdown of ductal architecture, with luminal necrosis and budding of cells into the 
lumen.  They also possess more extreme cytologic atypia with dystrophic goblet cells, prominent 
nucleoli, and mitotic figures43.  These histological changes correlate with increasing 
accumulations of the common mutations found in PDAC.  Telomere shortening is near universal 
in both PDAC and PanINs, and is commonly the first observable event in PanIN-1s44.  Another 
early event is activating mutations in the K-ras gene45 which are found in ~90% of PanIN-1 
lesions matching the  >90% of PDAC13, 19.   Loss of p16 expression occurs in 30% of PanIN1s, 
55% of PanIN2s, 70% of PanIN3s, and 95% of PDAC, suggesting a role for p16 in progression 
rather than initiation45, 46.  Loss of p16 generally occurs due to mutation or copy number loss, but 
can also be the result of promoter hypermethylation47.  PanIN lesions in the context of chronic 
pancreatitis are especially prone to p16 loss, marking this change as one way that inflammation 
may contribute to progression48.  Later genetic events in PanINs include inactivating mutation of 
TP53 (30-50%)49 and homozygous deletion of DPC4/SMAD4 (30%)41, 46, generally being 
observed only in PanIN-3 and PDAC.   
 Epigenetic alterations have also been identified in PanIN but are relatively understudied 
compared to the literature examining epigenetic alterations in PDAC.  Of a list of eight genes 
hypermethylated in invasive pancreatic cancer, Sato et al showed that at least one of the eight was 
aberrantly hypermethylated in 68% of 65 tested PanIN lesions50.  Additionally, PanIN3s were 
aberrantly methylated at an average of 2.9 loci in comparison to 1.1 loci in PanIN1s and PanIN2s 




Although many molecular alterations have been identified in PanINs, but perhaps 
surprisingly, it is still not known what molecular events are required for a PanIN-3 lesion to 
progress to an invasive PDAC.  Histologically, PanIN3s are rarely found in the absence of PDAC, 
and can be difficult to distinguish from PDAC due in part to the latter’s propensity for 
cancerization of nearby ducts 43, 46.  PDAC also frequently overgrows PanIN-3.  Both PDAC and 
PanINs harbor a high mutational burden of what are thought to be largely passenger mutations, 
making identification of novel drivers difficult51.  The size and low cellularity of these lesions 
constrain many researchers to using bulk tissue to characterize these lesions, adding a high 
potential for normal contamination and making isolation of PanIN3 signal from cancer even more 
difficult.  In a step to clarify this, Murphy et al utilized exome sequencing of microdissected 
samples from PDAC and adjacent PanINs.  They determined that >50% similarity existed 
between the mutations of 10 of the 15 isolated PanINs and their associated invasive cancer which 
































Major transcriptional changes occur during PDAC development.  Jones et al found that 
gene sets in the same 12 core signaling pathways commonly subject to mutation in PDAC were 
also enriched in differentially expressed genes compared to gene sets outside of these pathways 
(P < 0.001)17.    The number of differentially expressed genes in PDAC samples is extensive and 
has been reviewed elsewhere 52. Some of the well-known differentially expressed genes in PDAC 
include mesothelin 53, 54 which has for many years been studied as an immunotherapy target55.  
Other transcriptionally upregulated targets that have been evaluated as potential biomarkers for 
diagnosis include osteopontin56, MIC-157, several mucins58, and microRNAs (miRNAs) including 
miR20059 and miR129060.     Numerous genes have also been silenced in PDACs many of them 
epigenetically, including TFPI-261, RELN62, EYA263, SIP-164 and many others. 
Fewer studies have been performed to determine the transcriptional changes in PanINs.  
Expression analysis using cDNA microarrays by Prasad et al identified 49 differentially 
expressed genes in early PanIN lesions including extra-pancreatic foregut markers pepsinogen C, 
MUC6, KLF4, and TFF1 transcripts65. Another microarray study established HOXB2 as 
overexpressed in 38% of PDAC samples and 15% of PanIN samples66.  miRNAs overexpressed 
in PDAC including miR-21, miR-155, and miR-221 have also been shown to be overexpressed in 
high-grade PanINs67.  Sequencing of PanIN RNA is constrained by the difficulty of obtaining 
RNA from PanINs.  The microscopic scale of the lesions and their heterogeneous makeup 
necessitates the use of laser microdissection.  The extremely high level of RNase activity in 
pancreas compared to other tissues68 also makes it difficult to retrieve RNA of a yield and quality 
permissive to RNA-sequencing.   
Analyzing RNA-seq data  
As interest in RNA sequencing has grown in recent years, the number of available tools 




by Expectation Maximization) (http://deweylab.github.io/RSEM/) to quantify the transcript and 
gene abundances from paired-end reads in our samples.  A major advantage of RSEM is its 
ability to compensate for the ambiguity arising from reads that map to multiple transcripts/genes, 
a frequent and biologically-legitimate result in eukaryotic genomes.  RSEM does this by 
assigning reads to their most likely of many possible mapping loci based on a statistical model the 
tool generates from read quality and fragment length distribution69.  On simulated data, RSEM 
has proven especially robust in comparison to other tools when using paired-end reads at 
estimating the relative abundance of individual isoforms within a gene70.   
Limma is a program used to calculate differential expression from our RSEM counts 
(https://bioconductor.org/packages/release/bioc/html/limma.html ).  Our reason for choosing 
limma is that it is superior to other approaches at handling small sample sizes, due to its use of a 
parametric, empirical Bayes method.  In accounting for residual variance of genes, strength from 
other genes can be ‘borrowed’ due to the fact that all of them are fitted with the same linear 
model71, 72.  As our normal duct sample group has only three samples, this is an effective 
approach to stabilizing inference for our differential expression comparison.   
Neotranscription 
In the pursuit of identifying biomarkers for cancer screening, much focus has been placed 
on identifying overexpression of normal proteins.    Serum levels of Prostate Specific Antigen 
(PSA) has seen use as a screening tool and prognostic marker for prostate cancer73, but typically 
such markers are not very specific for cancer because overexpression can occur from non-
neoplastic causes 74.  Mesothelin is detectable in serum and consistently overexpressed by 
pancreatic cancer, but is not a useful diagnostic marker because it is also expressed in normal 




 One strategy to circumvent these problems is to focus on ‘neotranscription’, cancer’s 
propensity to generate novel coding transcripts.  One mechanism that achieves this is alternative 
transcription, in which the normal splicing machinery of the cell aberrantly splices coding 
transcripts to exclude and include a combination of novel exons.  A more stable mechanism is 
gene fusions, where chromosome breakage and rearrangement results in coding sequences from 
two different genes being fused into one novel transcript.  This can result in a potential oncogene 
being fused to the promoter of a highly expressed gene or, in rare cases, a hybrid protein with 
totally novel (and oncogenic) functionality.  The most famous of these events is the BCR/ABL 
fusion, a driving event of chronic myeloid leukemia76 that has proven to be one of the greatest 
successes of targeted therapy 77. 
Several challenges have made the detection of novel neotranscription difficult to identify.  
Alternative splicing is commonplace, occurring in most multi-exon genes in normal cells78.  As 
with the differential expression manifest in cancer cells, the vast majority of these events are 
likely to be passengers rather than drivers, and functional consequences of the inclusion or 
exclusion of different exons are rarely obvious by sequence alone.  Fusion events are much less 
common and are usually functionally significant.  Their identification requires the alignment of 
paired reads flanking the breakpoint (or a single read spanning it) to two different genomic loci, 
which is difficult for existing tools to distinguish from sequencing artifacts.   
 Limited neotranscription data exists for pancreatic cancer.  A characterization of the 
PDAC splicesome by microarray and RT-PCR found that the range of diversity seen in 
alternative splicing actually pointedly decreased in pancreatic cancer cell lines in comparison to 
normal cell lines. Additionally, the expression of a number of splicing factors was decreased in 
high grade pancreatic cancers, in contrast to other cancers79.  In a study of 100 pancreatic cancers, 




involved an orientation and frame likely to produce a functional transcript80.  An analysis using 
RNA-seq detected 50 productive fusion events in 13 PDAC samples81.  
 
Cytokine signaling Pathways in PDAC 
Chronic and acute inflammation contribute a rich milieu of cytokines to the 
microenvironment that can be exploited by cancers to promote growth.  Many of these cytokines 
work through the various JAK/STAT signaling pathways, in which the cytosolic transcription 
factor signal transducer and activator proteins (STATs) are phosphorylated by activated Janus 
kinases (JAKs)82, 83.  One example is the inflammatory cytokine interleukin-6 (IL-6), which in 
genetically engineered mouse models of PDAC is needed for the maintenance and progression of 
PanINs84 through the IL-6R/JAK1/STAT3 signaling axis.  In PDAC, STAT3 blockade inhibits 
growth85, 86.   
 IL-6 is just one of several inflammatory cytokines that mediates JAK/STAT signaling.  
Our transcriptional profiling of PanINs led to the identification of IL2RG as an overexpressed 
cytokine receptor. IL2RG binds to Interleukins 2, 4, 7, 9, 15, and 21 and once the IL2 receptor 
complex binds to ligand, IL2RG activates JAK187, JAK387, and phosphatidylinositol-3 (PI-3) 
kinase88.  This role makes IL2RG critical to the maintenance and functionality of the immune 
system; its loss causes severe combined immunodeficiency syndrome (SCID), a near-total 
absence of T and B-cells89.    IL2RG cytokine ligands have varied, overlapping downstream 
effects on proliferation, differentiation, and survival that have led to them being frequently co-
opted in haematopoietic malignancies90-92.  IL-4 and IL-4R are upregulated in and induce 





MATERIALS AND METHODS 
Laser microdissection 
Gross tissue samples were mounted on activated polyethylene naphthalate (PEN) slides 
and histologically graded for 3 normal ducts, 4 PanIN1A/Bs, 5 PanIN2s, and 9 PanIN3s.  Slides 
were immersed in RNAlater (ThermoFisher Scientific) and stored at -80º C.  Slides were stained 
with Cresyl Violet and laser microdissected on a Leica LMD6 within 20 minutes of thawing.  
RNA was harvested from microdissected cells (Arcturus PicoPure RNA Isolation Kit) and 
examined for concentration and quality using an Agilent Bioanalyzer with RNA 6000 Pico 
reagents.  Only samples with an RNA integrity score (RIN) score of >7 were sequenced. 
RNA-sequencing 
13 of the harvested samples (1 normal duct, 2 PanIN1s, 3 PanIN2s, and 7 PanIN3s) were 
converted to cDNA libraries using a Nugen Ovation RNA-Seq V2 kit with the SOLiD fragment 
protocol and sequenced on an Applied Biosystems SOLiD v. 5500 Wildfire.  Reads from this set 
were aligned using the Bioscope v1.3 Whole Transcriptome Plugin.  FPKM values were 
calculated using HTSeq-count (http://www-huber.embl.de/HTSeq/doc/overview.html).  The 
remaining 8 samples (2 normal duct, 2 PanIN1s, 2 PanIN2s, and 2 PanIN3s) were converted to 
cDNA libraries using the Nugen kit with the TruSeq protocol and sequenced on an Illumina 
HiSeq 2500.  Alignments and FPKM values for these samples were generated using rsem-1.2.9 
(http://deweylab.github.io/RSEM/).  FPKM values from the two sets of samples were combined 
using ComBat for batch removal.  Lists of differentially-expressed genes in comparisons between 
the different grades of PanINs and normal epithelium were generated using limma with an 
empirical Bayes method and fitted intensity trend.  Pathway analysis was conducted using the 





The HRP EnVision+ System (DAKO Corp.) was used to evaluate IL2RG protein 
expression in tissue microarrays (TMAs) using a rabbit anti-IL2RG antibody (Sigma-Aldrich; 
1:250 dilution) using methods previously described96.  Infiltrating lymphocytes were used as a 
positive control.  The relative intensity of labeling in neoplastic and normal duct cells  was 
qualitatively assessed as ‘negative’, ‘weak’, ‘intermediate’, or ‘strong’ for each TMA core based 
on the percentage of cells labeling. 
Cell culture: 
Mouse pancreatic cancer cell lines TB31456 and TB32043 were generously provided by 
Dr. Tuveson (Cold Spring Harbor Laboratory).  The mouse pancreatic cancer cell line bkpc58 
was generated by Dr. Anne MacGregor in the laboratory of Christine Iacobuzio-Donahue.  All 
human and mouse cell lines were cultured in DMEM supplemented with 10% heat-inactivated 
fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin (Gibco), and 2.5 mg/500 ml 
plasmocin (Invivogen) in 95% air and 5% carbon dioxide at 37º C.    
Organoid culture: 
 10,000 cells were pelleted at 4º C and resuspended in 4º C matrigel.  50 ul of matrigel 
were pipetted into the center of wells on a 24-well plate and placed in a 37º C incubator for 15 
minutes to solidify.  500 ul DMEM + 10% FBS + 1% penicillin/streptomycin was added to each 
well.  Media was changed every 3-4 days and cells were observed for signs of spherical growth.  
Cells were passaged by aspirating media, adding ice-cold media to dissolve matrigel, and 
pipetting the well contents into a 15-ml tube.  Organoids were pelleted, washed once with PBS, 





Total protein lysates were extracted in RIPA buffer (Roche Diagnostics, Indianapolis, IN) 
with cOmplete Mini tablets (Roche Diagnostics) and homogenized with a Bioruptor (Diagenode, 
Denville, NJ) for 8 cycles (30s high, 30S off).   Protein concentrations were determined using the 
Pierce BCA Protein Assay Kit (ThermoScientific, Waltham, MA).  Membranes were incubated 
overnight at 4º C with primary antibodies: rabbit anti-IL2RG (Santa Cruz Biotechnology, Dallas, 
TX), rabbit anti-JAK3 (Cell Signaling Technology, Danvers, MA), or goat anti-Actin (Santa Cruz 
Biotechnology).  Membranes were incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibody in 5% dry milk for 1 hour.  Bound antibody was detected with a Pierce ECL 
Plus kit (ThermoScientific). 
 
Generation of CRISPR plasmids 
CRISPR knockout experiments were performed with Cas9 nickase (Cas9n) enzymes 
guided by paired sgRNA sequences to mitigate off-target effects as previously described97.  
Paired sgRNA sequences targeting IL2RG on the X-chromosome were designed using the MIT 
CRISPR Design Tool (crispr.mit.edu) and synthesized by Integrated DNA Technologies: Pair 1: 
5’-TCTTAGTCCTTCAGCTGCTC-3’, 5’-GAGGGCAGGGTGGAGCTCCA-3’.  Pair 2: 5’-
TCCAGAGGTTCAGTGCTTTG-3’, 5’-TAGAGTACATGAATTGCACT-3’.  SgRNA 
oligonucleotides were annealed and ligated into digested pSpCas9n(BB)-2A-GFP (PX461) 
(Addgene, Cambridge, MA) utilizing the following reaction mix: 1 µl px461 (100 ng), 1 µl 
annealed oligonucleotides  (0.5 µM), 1 µl Bbs1 Fast-Digest (ThermoFisher Scientific), 2 10x 
Fast-Digest buffer (ThermoFisher Scientific), 1 µl T4 Ligase (ThermoFisher Scientific), 14 µl 
ddH20.  This mix was incubated in a 37ºC water bath for 2 hours and then transformed into Stbl3 
expression bacteria by heat shock (ThermoFisher Scientific).  Bacteria were selected by antibiotic 




Miniprep kit (Qiagen, Germantown, MD).  Harvested plasmid was Sanger sequenced to confirm 
appropriate insertion.   
Generation of CRISPR knockout clones: 
Cells were plated on 24-well plates at 1.3x105 cells/well 16-24 hours before transfection.  
Each well was transfected with 250 ng of each paired Cas9n plasmid (500 ng total) using 
Lipofectamine 2000 (ThermoScientific Fisher) according to the manufacturer’s protocol.  The 
TB32043 cell line was transfected with the IL2RG-targeting pair 1 Cas9n plasmids and the 
bkpc58 cell line was transfected with the IL2RG-targeting pair 2 Cas9n plasmids.  3 days after 
transfection, cells were flow sorted for GFP expression using a BSL 2 FACSAria II instrument 
into 96 well plates at 1 cell per well.  These cells were grown for 3 weeks before harvesting for 
DNA to test for the presence of CRISPR deletions. Genomic DNA from the female TB32043 cell 
line was cloned into TOPO vectors for Sanger sequencing according to the manufacturer’s 
protocol (TOPO TA Cloning Kit for Sequencing, ThermoScientific Fisher).   
Xenograft dissections: 
3x105 TB32043 cells or 1x105 bkpc58 cells were injected into the pancreas of 6-10 week 
old C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME).  Mice were sutured and followed 
daily for survival.  After 21 or 23 days, mice injected with TB32043 cells or bkpc58 cells 
respectively were sacrificed and dissected.  Cancers were weighed, immersed in RIPA buffer, and 
homogenized with a Tissue Disruptor to isolate protein for western blotting. 
In vitro proliferation: 
 Pancreatic cancer cell lines were seeded in the center 60 wells of 96-well plates at 3,000 
cells/well.  After 24 hours, media was replaced with normal media, L929-conditioned media, or 




hours of treatment, AlamarBlue was added to each well and cells were incubated for an additional 
4 hours.  Absorbance was measured at 490 nm using a BMG FluoStar Galaxy instrument. 
Statistical Analysis 
Descriptive statistical values and plots were generated using the Microsoft Excel software 
packages, Graphpad Prism 6.0, and R bioconductor.  For RNA sequencing analysis, lists of 
differentially expressed genes were generated using limma with an empirical Bayes method and 
fitted intensity trend.  Presented lists of genes were filtered to those differentially expressed with 




Differential expression in PanIN3s 
 21 tissue samples were laser microdissected and processed for RNA-sequencing analysis: 
3 normal pancreatic ducts, 4 PanIN-1, 5 PanIN-2, and 7 PanIN-3 samples.  In our principle 
component analysis of mRNA expression, we found that with one outlying exception, PanIN-3 
samples were the most divergent among PanINs from the normal ducts (Figure 2).  Using a q-
value threshold of 0.1, we identified 1723 genes differentially expressed between normal duct 
samples and PanIN-3 samples.  Table 1 lists the most differentially expressed genes with reported 
functional roles in cancer.  
     Some of the genes identified as overexpressed in PanIN-3 samples have been reported 
to have oncogenic properties. REG4 overexpression enhances the viability of PDAC cells. REG4 




normal tissues and has not been shown to be a specific circulating marker of PDAC 98.  FXYD3, 
which encodes FXYD Domain Containing Ion Transport Regulator 3, is similarly overexpressed 
in both PDAC and PanINs and has been reported to influence pancreatic cancer growth99.  
WFDC2 (HE4), a well known circulating marker of ovarian cancer, has been shown to be 
overexpressed in pancreatic cancers and elevated HE4 levels have been described in the sera of 
some patients with PDAC100.   
Concurrently, several genes with cancer suppressive properties known to be silenced in 
PDAC were also found to be markedly underexpressed in the PanIN3 samples.  TFPI2 and RELN 
are both frequent targets of silencing by DNA hypermethylation in pancreatic cancer and 
IPMNs62, 101,102.  Loss of expression of p21, which was also found to be underexpressed in our 
PanIN3 samples, has also been reported to occur in pancreatic cancer and to be associated with 
metastasis, dedifferentiation, and poor prognosis103.   
We generated lists of differentially expressed genes between each PanIN grade and 
normal duct samples.  All lists included here are of the 50 genes with the lowest adjusted p-value 
for differential expression within their comparison.  In Table 2, we list the genes exclusively 
overexpressed in PanIN3 samples in comparison to normal duct samples (i.e. not overexpressed 
in PanIN1 or PanIN2 samples).  In Table 3, we list the genes overexpressed in a pooled sample 
group of all 3 PanIN grades in comparison to normal duct samples.  Finally in table 4, we list the 
genes underexpressed in PanIN3 samples in comparison to normal duct samples. 
We used immunohistochemistry to examine the expression of the protein products of 
several genes identified as differentially expressed by RNA-seq. Through immunohistochemistry 
analysis of TMAs, we found REG4 to be overexpressed at the protein level in PDAC and PanINs.  
The overwhelming majority of cores containing normal pancreatic duct featured weak 




the PanIN-1A cores, 40% (2/5) were weakly labeled, 20% (1/5) were intermediately labeled, and 
40% (2/5) were strongly labeled.  Of the PanIN-1B cores, 11.11% (1/9) cores were intermediately 
labeled, and 88.89% (8/9) cores were strongly labeled.  Of the PanIN-2 cores, 42.85% (3/7) cores 
were intermediately labeled and 57.14% (4/7) cores were strongly labeled.  Of the PanIN-3 cores, 
20% (2/10) cores were intermediately labeled and 80% (8/10) were strongly labeled. Of the 
PDAC cores, 100% (5/5) were strongly labeled.  (Figure 1).  
IL2RG expression 
 While many of the differentially expressed genes found in PanIN have been reported to 
be similarly differentially expressed in PDAC, there were notable exceptions such as IL2RG.  In 
our dataset, IL2RG is overexpressed in PanIN3 samples by an average log fold change of 4.43 
over normal ducts (Figure 1A).   
To confirm that our microdissection was performed to isolate pure cell populations, we 
checked if other lymphocyte markers were enriched in our PanIN samples. PTPRC (CD45) and 
CD3D are two transcriptional markers for lymphocytes.  We find no significant correlation 
between lymphocyte signature genes and IL2RG expression in our samples (PTPRC =-
0.2454545, p-value = 0.2822, CD3D =  -0.2285714, p-value = 0.3175), suggesting that IL2RG 
overexpression is not the result of increasing lymphocyte infiltration in higher grade PanINs that 
was not microdissected (Figure 1B).  Overlaying our expression data on the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway for JAK-STAT signaling, we observe that several other 
genes downstream of IL2RG signaling are up- or downregulated in a direction consistent with 
pathway activation (Figure 5). 
 We sought to assess protein expression of Il2rg in patient PDAC, PanIN, and IPMN 
lesions by immunohistochemistry on tissue microarray slides (Figure 2).  The PanIN TMA 




PanINs showed a progressively increase in the percentage of intermediate and strong staining 
lesions with grade (1A: 0/7 cases, 0%, 1B: 1/5 cases, 20%, 2: 4/12 cases, 33%, 3: 6/14 cases, 
43%, cancer: 5/9 cases, 56%).  IPMNs also displayed overexpression compared to normal 
pancreatic ducts.  Similarly, in the PDAC TMAs, the majority of cancer samples presented with 
intermediate or strong labeling (38/53 cases, 71.70%) while the vast majority of normal ducts 
featured negative or weak staining (27/29 cases, 93.10% ). 
The factors regulating expression of IL2RG remain unknown.  Although a direct link has 
not yet been demonstrated, the MECOM transcription factor (MDS1 and EVI1 complex locus) 
has a consensus sequence binding site in the IL2RG promoter identified through the Transfac 
database (http://www.gene-regulation.com/pub/databases.html).  MECOM has also been found to 
induce KRAS through suppression of the KRAS-inhibitory microRNA-96 in pancreatic cancer104.  
In our dataset, MECOM RNA is overexpressed in PanIN3 samples by a log fold change of 3.77 
over normal ducts (Table 1). 
 We next examined Il2rg protein expression in human PDAC cell lines.  By western 
blotting, we were unable to detect Il2rg in any of our tested cell lines (Figure 7) consistent with 
the lack of RNA expression in pancreatic cancer cell lines by Serial Analysis of Gene Expression 
(SAGE);  elevated levels of IL2RG transcripts were present in primary PDAC but no expression 
was present in human PDAC cell lines17.  There is evidence that Il2rg expression is rapidly lost in 
vitro 105. This is consistent with the known rapid change in expression of Il2rg and its downstream 
binding partner Jak3 and subsequent pathway activation/inactivation in response to stimuli in 
lymphocytes106. 
 With this in mind, we hypothesized that IL2RG expression may be dependent on in vivo 




orthotopically implanted mouse PDAC cell line and identified two of five with expression of 
Il2rg (Figure 4A).   
These cell lines were cultured are harvested for protein to assay for Il2rg expression.  In 
the absence of a suitable antibody for mouse Il2rg , but it is known that the expression of IL2RG 
and JAK3 are tightly linked 107.  We were unable to detect Jak3 in either cell line by western blot 
(Figure 4B), supporting the hypothesis that pancreatic cancers can express Il2rg in vivo but not in 
vitro.  L929 is a fibroblast mouse cell line used to condition media for macrophage differentiation 
that secretes several cytokines including GM-CSF which has been reported to be an  Il2rg 
ligand108.  We found that conditioning our cell lines with L929-conditioned media did not induce 
IL2RG expression (data not shown).  
We also examined if IL2RG expression could induced by growing pancreatic cancer cells 
as organoids but did not find pancreatic cancer organoids expressed Il2rg 
 
Generation of IL2RG knockout clones using CRISPR/Cas9 
 We resolved to knockout IL2RG from mouse pancreatic cancer cell lines using the 
CRISPR/Cas9 system.  Mouse cancer cells were chosen so that we could examine the effect of in 
vivo growth after IL2RG knockout. Cells were transfected with plasmids containing the Cas9 
nickase enzyme and pairs of guide RNAs targeting exons 1, 2, and 3 of IL2RG.  Clones were 
isolated and tested for genome editing by Sanger sequencing.  We initially identified no clones 
featuring homozygous deletion of IL2RG but several heterozygotes.  One of these heterozygotes 
was retransfected with the same IL2RG-targeting pair 1 plasmids and flow sorted as previously 
described.  One of the resulting clones was Sanger sequenced and found to harbor a homozygous 




alleles requiring editing as IL2RG is on the X-chromosome.  Genomic DNA from a male bkpc58 
clone was confirmed by Sanger sequencing to have a homozygous deletion in IL2RG. 
  The two clones identified with genomic deletions in IL2RG were a 32043 clone with a 52 
base pair deletion in exon 1, and a bkpc58 clone with a 104 base pair deletion in exon 3 (Figure 
4C). 
Impact of IL2RG loss on the in vitro growth of cell lines 
 We hypothesized that it may be possible to induce IL2RG expression and response to 
IL2RG ligands in our cell lines.  We treated our wild type and IL2RG knockout cell lines with 
L929 media to test this possibility.  After three days of treatment, we assayed the number of 
metabolically-active cells using AlamarBlue (Figure 10).  Although we observed a significant 
induction of proliferation in the wild type cells and not the IL2RG knockout cells in some 
experiments, this result proved inconsistent across replicates.  We hypothesize that this may be 
the result of batch variance in the cytokine complement of our L929 media harvested on different 
dates. 
 We additionally tested whether proliferation could be induced by treatment with a high 
dose of Il2RG ligands.  IL-4, GM-CSF, and IL-7 were selected based on the expression of 
downstream signaling targets observed in the PanINs highly-expressing IL2RG.  We repeated our 
proliferation experiment replacing L929 media with normal media supplemented with 100 ng/ul 
of IL-4, GM-CSF, or IL-7 (Figure 11).  In all three cases, we observed no significant induction of 
proliferation in wild type or IL2RG knockout cell lines. 
Impact of IL2RG loss on the growth of orthotopically implanted pancreatic cancer cells  
We compared the growth of the parental and knockout clones in vitro and found no 




mice to determine what effect IL2RG loss would have on in vivo tumorigenesis.  After 21 days for 
line 32043and 23 days for line bkpc58, injected mice were sacrificed and cancer weights were 
compared. There was no significant difference in cancer growth between wild type and unedited 
xenografts but a significant reduction in the weight of IL2RG knockout xenografts: TB32043 
30.75% ± 10.43% (p-value = 0.0001), bkpc58 29.58% ± 12.58% (p-value = 0.0133)(Figure 5A).  
Additionally, western blot analysis of the 32043 cell line xenografts showed significantly higher 
expression of JAK3 in the parental vs. knockout cells (p-value = 0.0156) (Figure 5B) consistent 
with reduced pathway activation in the knockout cells. 
 
DISCUSSION 
 In this study, we demonstrate that PanINs and PDAC overexpress the common gamma 
chain, IL2RG.  Our ability to detect this overexpression highlights the utility of using 
microdissected samples for transcriptional profiling.  CRISPR-induced truncating mutations of 
IL2RG in two different cell lines resulted in significantly reduced cancer growth in orthotopic 
xenografts and reduced expression of its signaling partner JAK3, supporting a functional role for 
IL2RG in pancreatic cancer cells. 
 The lack of an in vitro model of IL2RG expression in pancreatic cancer cells presents 
challenges for the further characterization of this pathway. In the literature, it has been reported 
that a functional receptor hybridizing granulocyte/macrophage colony stimulating factor receptor 
β (GM-CSFRβ) and IL2RG expression has been reported to be present in hematopoietic CD34+ 
cells responding to granulocyte/macrophage colony stimulating factor (GM-CSF)109.  This 
cytokine was recently shown to promote the growth, invasion, and metastatic potential of 




IL-4, which has been reported to enhance proliferation of several IL-4RA-expressing human 
pancreatic cancer cell lines111, although evidence pointed to signaling occurring through an 
alternative receptor complex.  This study is also at odds with our observation that Il2rg is not 
expressed in vitro by pancreatic cancer cell lines. 
 Coreceptors of IL2RG have been successfully targeted in other cancer types.112 113  Our 
results raise the possibility that there could be value in targeting this pathway therapeutically. 
There are JAK3 inhibitors in use in the clinic for the treatment of rheumatoid arthritis 
(PMID25047498).  Thus, a JAK3-specific inhibitor such as Tofacitinib that could inhibit the 
growth of IL2RG-expressing pancreatic cancer cells could potentially have efficacy in patients.  
Tofacitinib has been reported to reduce cancer growth in xenograft models of human T-cell 
lymphoma114. 
Early studies suggested that other JAK inhibitors might have a role in treating pancreatic 
cancer115, 116.  However, a phase 3 clinical trial using Ruxolitinib, a JAK1 inhibitor, for patients 
with advanced pancreatic cancer was recently terminated due to disappointing efficacy117. 
Clinical trials for Momelotinib, a JAK1/2 inhibitor, in combination with Gemcitabine and Nab-
paclitaxel are ongoing (https://clinicaltrials.gov/show/NCT02101021).  Notably, these clinical 
trials were undertaken to determine the efficacy of using this momelotinib to target immune cells 
in the cancer microenvironment, not pancreatic cancer cells themselves.  In canonical Il2rg 
signaling, JAK1 dimerizes with JAK3 immediately downstream of the receptor.  It is possible that 
these inhibitors may inhibit Il2rg signaling in cancers expressing it. 
 Beyond the possibility of chemotherapeutic targeting, IL2RG expression may hold 
implications for pancreatic cancer immunotherapy118.  Researchers are exploring the use of 
administered cytokines, both alone and in conjunction with vaccines, to stimulate activation and 




tumor microenvironment.  Clinical studies of preoperative administration of IL-2 have shown 
increases in survival and progression free survival of pancreatic cancer patients119, 120.  Systemic 
IL-2 is being used in an ongoing clinical trial for a vaccine targeting P53 + Ras (NCT00019084 
and previous, now suspended trial for a vaccine targeting CEA (NCT01723306).  Although these 
trials have been focused on stimulating vaccine response, it is possible that IL-2 could stimulate 
proliferation of cancers expressing Il2rg.   
In conclusion, we find that IL2RG is expressed at the earliest stages of pancreatic cancer 
with a significant role in tumorigenesis.  Further study is required to elucidate its precise 
mechanism of action and potential as a therapeutic target.  Of particular interest would be 
identifying which (if any) of the several possible ligands are stimulating IL2RG and if the 


















Table 1.  Highlighted transcripts differentially expressed between normal duct samples and 
PanIN3s. 
ID Log2 Fold Change  Average Expression  Adjusted p-value 
REG4 -7.38599 5.30466 0.023446 
FXYD3 -5.07836 5.840235 0.000135 
WFDC2 -4.78364 5.183681 0.020943 
ANXA10 -4.51085 5.467628 0.01682 
IL2RG -4.43129 3.516513 0.00111 
MDK -4.28123 4.562996 7.37E-05 
CLDN18 -4.17368 7.513807 0.013711 
TXNIP -4.13336 6.549126 0.003369 
CTSE -4.00825 8.741542 0.049768 
PPARG -3.97045 3.8431 2.11E-06 
MECOM -3.76696 4.570754 3.75E-05 
NQO1 -2.45764 5.339688 0.001632 
IDH1 -2.40941 4.138584 0.008271 
TIMP1 -1.55919 6.426763 0.01714 
CDKN1A 2.359616 5.176117 0.033195 
TFPI2 3.676845 1.258874 9.62E-06 
RELN 3.994777 1.305201 0.000128 
SPP1 4.38009 3.243471 0.02906 







Table 2.  Transcripts overexpressed in PanIN3s (exclusively among PanINs) vs normal duct 
samples.  These 50 transcripts had the lowest observed adjusted p-value of those in the 
comparison. 
 
ID  Log 2Fold 
Change  
Average Expression  Adjusted p-value  
RRM2  -1.9140  1.4590  0.0007  
COTL1  -1.9507  1.7187  0.0010  
DLEU7  -4.4313  3.5165  0.0011  
CDHR2  -2.9820  1.5269  0.0024  
PTK6  -1.5232  0.9612  0.0027  
PSMC1P2  -2.9991  1.8893  0.0029  
SDR16C5  -3.2507  2.3845  0.0029  
CFL1P5  -0.9414  0.8916  0.0035  
SFT2D2  -1.9217  3.2840  0.0045  
LGR4  -2.2449  4.7128  0.0045  
HIST2H2AA3  -2.0518  3.2689  0.0062  
OR5M11  -1.1188  1.5083  0.0072  
TCF7L2  -1.4152  4.9378  0.0079  
C4BPB  -3.0528  4.1796  0.0084  
NAV1  -0.8635  4.2727  0.0091  
IHH  -1.5999  2.3632  0.0094  
ESRP1  -1.4203  2.8652  0.0106  
SRD5A1  -2.1433  2.1493  0.0110  




KIF18B  -1.2251  1.2764  0.0118  
REXO2  -2.0702  2.1871  0.0125  
C10orf10  -2.5738  2.3101  0.0140  
NFE2L1  -0.7765  2.1765  0.0142  
PARP3  -1.5804  2.6449  0.0142  
B3GNTL1  -1.2879  2.9137  0.0147  
AP2M1  -0.7532  0.7778  0.0150  
CST1  -1.0883  2.9051  0.0153  
UBE2C  -0.9914  1.9686  0.0155  
ZDHHC9  -1.4257  2.2199  0.0155  
HOXB7  -0.9832  4.9748  0.0158  
EZH2  -0.7633  1.2502  0.0159  
LRRC31  -1.0461  2.9554  0.0164  
PI3  -4.5108  5.4676  0.0168  
PNMA1  -1.0149  0.6347  0.0170  
PGM2L1  -1.8820  2.7490  0.0174  
PSMB5  -1.3387  1.6433  0.0178  
OASL  -0.9336  1.6202  0.0183  
HIST1H2AI  -2.1301  2.2790  0.0189  
SEC16B  -0.7911  0.5556  0.0190  
CIT  -0.7100  1.9789  0.0192  
GPI  -0.6109  0.6424  0.0202  
FAM162A  -1.9028  3.7472  0.0204  
IGF2BP3  -0.9323  2.4589  0.0209  
FER1L4  -2.5120  4.1109  0.0209  




MYBL2  -1.5384  2.6855  0.0214  
CCNG2  -2.1469  2.6027  0.0218  
GRN  -1.5119  2.3488  0.0221  
DAPP1  -0.9239  3.9139  0.0223  























Table 3.  Transcripts overexpressed in collective PanINs (1s, 2s, 3s) vs normal duct samples.  
These 50 transcripts had the lowest observed adjusted p-value of those in the comparison. 
 
ID log2 Fold Change Average Expression Adjusted p-value 
LIN7A 0.8230 0.7511 0.0004 
MTUS2 0.7124 0.6129 0.0004 
LYPD6B 2.0132 4.0781 0.0004 
C3orf45 1.2850 1.1219 0.0004 
GUCA2A 1.0463 0.7278 0.0004 
NOSTRIN 1.2269 3.9486 0.0004 
AKAP7 1.0568 1.5492 0.0004 
VGLL1 1.1566 0.9448 0.0004 
STEAP4 1.6482 1.6987 0.0004 
SOX6 0.9508 1.5692 0.0005 
DTNA 0.9268 0.7952 0.0005 
CCDC141 0.5392 0.5739 0.0008 
CALN1 0.5788 0.5917 0.0008 
CADM1 1.0328 1.1690 0.0008 
GABRA5 0.6764 0.5324 0.0010 
LRRC7 0.6799 0.5073 0.0010 
SLC2A2 2.3039 1.8808 0.0010 
SLCO4C1 0.9252 0.8117 0.0011 




CNR1 0.5538 0.5364 0.0017 
TGFB2 1.6434 1.4661 0.0018 
GPR64 1.3701 1.7352 0.0018 
MTUS2-
AS1 
0.7541 0.5469 0.0018 
POU6F2 1.1592 0.9124 0.0018 
DSCAML
1 
1.0114 0.7466 0.0018 
NR1H4 1.4736 1.1337 0.0022 
NUCB2 2.0968 2.7005 0.0022 
METTL7
A 
1.0773 3.1398 0.0025 
NME5 1.3781 1.6224 0.0025 
ALDH1A2 0.8765 0.7939 0.0025 
VEPH1 0.7521 0.7368 0.0028 
ZNF704 0.7882 2.4856 0.0028 
ZNF135 0.6310 0.6585 0.0028 
EFEMP1 1.6396 1.6833 0.0028 
GLIS3 2.3102 2.9767 0.0029 
WNK2 0.7345 0.8225 0.0033 
RALYL 1.6245 1.2176 0.0039 
SETBP1 0.9642 1.5749 0.0039 
TTLL7 1.4302 1.6411 0.0044 
CASP9 0.9464 1.7125 0.0044 
ZFP36L2 1.0260 6.2748 0.0044 
BCO2 1.3985 1.3799 0.0047 






1.3708 2.3320 0.0049 
DDIT4 5.3228 4.3957 0.0050 
HYDIN 0.5354 0.5834 0.0050 
DYRK3 0.8975 1.2922 0.0051 
BCL2 0.7139 1.0227 0.0054 
BEX5 2.3786 2.1284 0.0057 



















Table 4.  Transcripts underexpressed in PanIN3s vs. normal duct samples.  These 50 
transcripts had the lowest observed adjusted p-value of those in the comparison. 
 
 
ID log2 Fold Change Average Expression Adjusted p-value 
VGLL1 3.4168 0.9448 1.38E-08 
AKAP7 2.9597 1.5492 1.38E-08 
GUCA2A 2.8986 0.7278 1.38E-08 
LIN7A 2.2845 0.7511 1.38E-08 
GABRA5 2.0514 0.5324 1.38E-08 
MTUS2 1.9404 0.6129 1.38E-08 
CALN1 1.7263 0.5917 1.38E-08 
CCDC141 1.5185 0.5739 2.21E-08 
CNR1 1.6342 0.5364 5.05E-08 
LRRC7 1.8733 0.5073 6.20E-08 
SLCO4C1 2.5472 0.8117 6.86E-08 
DOK5 3.3269 1.0830 8.84E-08 
POU6F2 3.2967 0.9124 8.84E-08 
ALDH1A2 2.6025 0.7939 8.84E-08 
TMEM27 2.4447 0.8127 8.84E-08 
STEAP4 3.8134 1.6987 1.25E-07 
MTUS2-
AS1 
2.0858 0.5469 1.25E-07 
DTNA 2.1122 0.7952 2.52E-07 
C3orf45 2.6853 1.1219 3.05E-07 




NOV 3.4220 1.2958 8.12E-07 
NOSTRIN 2.3365 3.9486 8.26E-07 
VEPH1 1.9311 0.7368 8.75E-07 
SLC17A4 4.2270 1.6212 1.19E-06 
EFEMP1 4.0484 1.6833 1.48E-06 
BCO2 3.6607 1.3799 1.53E-06 
ATP10A 1.6310 0.7804 1.57E-06 
KIAA0319 1.7509 0.7370 1.73E-06 
WNK2 1.8183 0.8225 1.86E-06 
KRT4 1.2670 0.5602 1.86E-06 
DSCAML
1 
2.2920 0.7466 2.20E-06 
PAH 3.3364 0.8778 2.24E-06 
NR1H4 3.3489 1.1337 2.61E-06 
SOX6 1.8174 1.5692 2.80E-06 
CYP39A1 1.1183 0.5530 2.93E-06 
CNTN4 1.5465 0.7198 3.15E-06 
SIM1 1.9766 0.6375 3.41E-06 
SETBP1 2.2357 1.5749 5.57E-06 
HYDIN 1.2654 0.5834 6.74E-06 
KCNMA1 2.2177 0.8478 8.51E-06 
ANGPT1 1.4105 0.6487 8.51E-06 
BCL2 1.6681 1.0227 8.80E-06 
APCDD1 4.9079 2.4655 8.93E-06 
CYS1 2.3736 0.9061 8.93E-06 






3.3514 1.5053 9.36E-06 
TFPI2 3.6768 1.2589 9.62E-06 
C8orf42 2.9061 1.2862 9.70E-06 
GRM8 0.9407 0.4561 1.08E-05 



















Figure 1.  Example pancreatic lesions dissected for RNA.  All slides were stained with 














Figure 2. Circos and PCA plot of normal and PanIN samples.  Red = normals, green = 
PanIN1s, blue = PanIN2s, purple = PanIN3s.  Each grade of samples shows greater divergence in 
transcript expression than the last from normal and other samples of the same grade.  Of the 9 












Figure 3.  MA plots of differential expression comparisons.  Each dot represents a gene.  
Interestingly, PanIN3s trend more towards underexpressing a greater number of genes in 












Figure 4.  Immunohistochemical  analysis of REG4 expression in pancreatic lesions.  PanIN1 












Figure 5. IL2RG mRNA expression in PanINs.  (a) IL2RG mRNA expression was assessed with 
limma and transcript per million (TPM) values were averaged for each PanIN grade.  (b) mRNA 
expression of PTPRC and CD3D, two lymphocytic markers used here to assess immune 
infiltration, did not increase in higher-grade PanINs.  (c) The results of the differential 
comparison analysis of normal duct and PanIN3 samples were overlaid on the KEGG JAK-STAT 
pathway using Gage and Pathview Bioconductor tools.  Several additional genes interacting with 
or targeted by the IL2RG signaling pathway are differentially expressed.  Red = overexpressed in 
PanIN3s (adjusted p-value < 0.1), green = underexpressed in PanIN3s relative to normal duct 



























































Figure 6.  Immunohistochemical analysis of IL2RG expression in tissue microarrays.  
Normal pancreatic ducts have weak or negative labeling of IL2RG.  PanIN and PDAC lesions 





















Figure 7.  Western blot analysis of IL2RG protein levels in pancreatic cancer cell lines.  NK-
92, a natural killer cell line, and patient tumor 26935 are positive for IL2RG expression.  All 












Figure 8.  Immunohistochemical analysis of IL2RG expression.  A)  Human tissue pancreatic 
microarrays.  Normal ducts do not label, PanINs label weakly, and PDAC labels intensely.  B)  

















Figure 9.  Electropherograms of IL2RG CRISPR-deleted regions in mouse cell lines.  A)  
TB32043 is a female line with a biallelic  52 base pair deletion in exon 1 of IL2RG.  B)  bkpc58 













Figure 10.  L929-induced proliferation of IL2RG knockout mouse pancreatic cancer cells.  
Cells were treated with L929-conditioned media for 72 hours and then assayed for metabolically 
active cells using AlamarBlue.  Although a significant induction of proliferation was observed in 
the wild type cells (and not IL2RG knockout cells) of some experiments, this result proved 












Figure 11.  IL2RG ligand induced proliferation in IL2RG knockout mouse pancreatic 
cancer cells.  Cells were treated with 100 ng/ul of one IL2RG ligand: IL-4, GM-CSF, or IL-7.  
After 3 days, proliferation was measured using AlamarBlue to assay for metabolically active 













Figure 12.  Phenotype of IL2RG CRISPR-edited xenografts.   There is no significant difference in 
the tumor weight of the wild type and CRISPR-treated (but unedited) xenografted  A) TB32043 
and B) bkpc58 cells.  In contrast, A) TB32043 and B) bkpc58 cells with IL2RG knockout have 














Figure 13.  JAK3 expression in xenografted TB32043 cells.   A) Xenografted IL2RG WT cells have 
significantly higher expression of JAK3 than IL2RG CRISPR-edited cells (NK-92 = human natural 

































MATERIALS AND METHODS 
Alternative Transcription Analysis 
AltAnalyze (www.altanalyze.org) was run on BED files for RNA-sequencing data from 
12 samples: 3 normal pancreatic duct and 9 PanIN3s.  Species was set to human and the 
EnsMart65 database was used as a reference.  The ASPIRE algorithm, described in detail in the 
AltAnalyze manual (http://www.altanalyze.org/help_main.htm , section 3.2), was used to score 
exon inclusion/exclusion events.  In brief, a ratio is calculated separately for the inclusion and 
exclusion of a reciprocal junction, in which expression of the junction is divided by the mean of 
all gene expression reporting junctions and exons.  The experimental group (PanIN3) vs. control 
(normal duct) ratios were then calculated, along with a false-discovery rate p-value (Benjamin-
Hochberg correction).  Lineage Analysis was performed by calculating correlation coefficients of 
the sample groups to Lineage WikiPathways networks. 
 
RT-PCR 
To examine levels of alternatively spliced transcripts in PDAC, RNA was harvested from 
pancreatic cancer cell lines and pancreatic cancer patient tumor samples.   1 µg total RNA from 
each sample was reverse transcribed using QuantiTect Reverse Transcription Kit (Qiagen) 
according to the manufacturer’s protocol.  The resulting cDNA was diluted 1:200 on the ABI 
7300 Real-Time PCR thermocycler (Applied Biosystems) using SYBR Green PCR Master Mix 
and recommended PCR conditions (Applied Biosystems).  Melting curve analysis and 
normalization to 18S rRNA was performed. 
Primers were designed to target isoform-specific regions of MUC1, ANXA2, and 
MYO10 and ordered from Integrated DNA Technologies (www.idtdna.com):  
 ANXA2 Normal Isoform F1 5’- CCAGGGTGAAAATGTTTGCCA 




 ANXA2 PanIN3 Isoform F1 5’- GGCTGCCCACTTCCTTCAAA 
 ANXA2 PanIN3 Isoform R1 5’- TCCCGCTCAGCATCAAAGTT 
 MUC1 Normal Isoform Exon5-6 F1 5’- AGCGTGAGTGATGTGCCATT 
 MUC1 PanIN3 Isoform Exon5-6 F1 5’- TCAGCGGCTGTCTGTCAGT 
 MUC1 Isoform-Agnostic Exon5-6 R1 5’- CGCCCATGGGTGTGGTAG 
  
 MYO10 Full Isoform F1 5’- GATAACTTCTTCACCGAGGGAACA 
 
 MYO10 Full Isoform R1 5’- CCGGCTGTACTGCTCCATGGTGGCAG 
  
 MYO10 Headless Isoform F1 5’- CAGCACAGCCCGAGACGCAC 
 
 MYO10 Headless Isoform R1 5’- CTTGGGTTTTCTTTCACCCCTTCAG 
 
RNA in situ hybridization 
 
 Proprietary probes targeting bases 1262-2318 of the NM_012334.2 transcript sequence 
for fMYO10 were designed and manufactured by Advanced Cell Diagnostics (www.acdbio.com).  
RNAscope assay was performed according to the manufacturer’s protocol with the 2.0 HD RED 
Assay on tissue microarrays (TMAs) of pancreatic normal and cancer spots.  A total of at least 
1000 cells were examined from each group and red staining foci were counted.  Foci were 
normalized to the number of cells counted from each group. 
 




Hairpin shRNA sequences targeting isoform-specific regions of MYO10 were designed 
with the Oligoengine software (www.oligoengine.com) and ordered from Integrated DNA 
Technologies (www.idtdna.com):  
 
Fusion detection analysis 
BED files from 8 samples (2 normal duct, 2 PanIN1, 2 PanIN2, 2 PanIN3) were analyzed 
with Tophat-fusion (http://ccb.jhu.edu/software/tophat/fusion_index.shtml).  The fusion minimum 
distance was set to 100000000 and anchor length to 13. Tophat-fusion-post results were further 
filtered using Oncofuse (www.unav.es/genetica/oncofuse.html).  Finally, events meeting any of 
the following criteria were filtered out: 
1. Fusion event reported in normal sample 
2. Fusion event includes a gene and partnered pseudogene. 
3. Fusion partners are not in parallel or coding orientation. 
RESULTS 
 The AltAnalyze lineage profiler compares sample expression data to a database of tissue-
specific lineage profiles of transcription markers generated by AltAnalyze from public 
Affymetrix and GEO repositories of Affymetrix Exon 1.0 data.  We performed this analysis on 
our samples.  The pattern of isoform expression in  our normal duct samples correlated very 
strongly with the pancreas lineage profile and little else.   The isoforms expressed in our PanIN1 
samples correlated most-strongly with the pancreas lineage profile, but had positive Z scores for a 
few other tissues.  Isoform expression in both PanIN2 and PanIN3 samples showed little 
correlation to the pancreas lineage profile and much stronger correlations to the lineage profile of 




              We compared the transcriptional profiles of PanIN3 and normal duct samples.  We 
generated a list of 3053 exon inclusion events mapping to known genes.  We did not observe a 
reduction in splicing diversity that had been reported in pancreatic cancer cell lines79.   1200 of 
the 3053 events were predicted to result in a downregulation of the corresponding isoform in 
PanIN3s and 1853 were predicted to result in an upregulation.   
Many of the alternatively spliced transcripts were of unknown biological significance, but 
a few stood out based on literature review and were selected for follow up (Table 2).  The MUC1 
gene possesses a variable number of tandem repeats (VNTR) region and has 20 amino acids 
subject to variable O-glycosylation.  In over 80% of pancreatic adenocarcinomas MUC1 is 
differentially glycosylated which can affect the chemosensitivity of cancer121.  In our list of 
candidate alternatively spliced transcripts, two of the highest scored (-0.82345, adjusted p-value = 
0.00013 ;-0.74755, adjusted p-value = 0.00117) occur in MUC1.  These splicing events map to an 
isoform previously described as oncogenic122.  Annexin 2 (ANXA2) has several alternative 
splicing events, including one highly-scoring for inclusion in PanIN3s over normal ducts (-
0.63655) that suggests a switch between two known isoforms.  The functional significance of 
these isoforms is unknown, but ANXA2 is being investigated as a target for immunotherapy 123.   
                Three of the highest-scoring events (-0.75227, -0.72576, -0.72576) were for Myosin X 
(MYO10) transcripts, an unconventional myosin that acts to form filopodia on the cell surface 
(Berg, 2002).  MYO10 has recently been established as playing an important role in cancer 
invasion and metastasis through construction of invadopedia, cell protrusions that are capable of 
penetrating and digesting extracellular matrix (Schoumacher 2010).  MYO10 knockdown results 
in a considerable reduction of invadopedia formation and matrix digestion (Cao 2014).  MYO10 
overexpression promotes aggressiveness and metastasis in breast cancer, and its expression is 
induced in pancreatic cancer by the introduction of mutant p53 in mouse models 124, 125 .  




                MYO10 consists of two functionally-distinct isoforms, “full” (fMYO10) and “headless” 
(hMYO10).  fMYO10 is connected to mitosis and cell migration in neurons, while hMYO10 is a 
dominant negative inhibitor of full126.  The three splicing events reported correspond to inclusion 
of exons 18 and 19, which are part of the fMYO10 isoform.  Counts of this inclusion event 
indicate that PanIN3s undergo a drastic alternative splicing event from a full : headless ratio of 7 : 
42 in our normal duct samples to 56 : 7 in our PanIN3s.  Notably, in our differential expression 
comparison, MYO10 fell short of the threshold for significance with an upregulation of 2.07-fold 
over the normal duct samples (Figure 4).  Multiplying this fold-ratio by the calculated isoform 
ratio, PanIN3s upregulate fMYO10 by 16.57-fold over the normal ducts and downregulate 
hMYO10 by 3-fold. 
                We sought to corroborate our in silico findings through RT-PCR with isoform-specific 
primers for MUC1, ANXA2, and MYO10 (Figure 3).  In all three genes, alternatively spliced 
isoforms implicated by our splicing analysis to be overexpressed in PanINs relative to normal 
pancreatic duct samples were also overexpressed in pancreatic cancer cell lines Panc5.04, 
MiaPaCa2, and Panc8.13 in comparison with the non-neoplastic pancreatic duct line HPDE.  
Both isoforms of MUC1 had comparable expression in pancreatic cancer cell lines, while for 
ANXA2 the normal isoform was proportionately more overexpressed than the PanIN isoform.  
With MYO10, we saw much greater overexpression of the full, putatively oncogenic, isoform 
than the headless isoform in pancreatic cancer cell lines in comparison to HPDE.   
MYO10 
 In order to confirm the cellular source of MYO10 isoform transcripts, we performed 
RNA in situ hybridization on tissue microarrays containing PDAC and normal pancreas tissues 
with probes targeting isoform-specific regions of fMYO10.  Primary pancreatic cancer cells had a 




much smaller than determined by RNA-seq data: Normal duct: 248 foci in 1243 cells (0.20 
foci/cell); pancreatic cancer: 445 foci in 1003 cells (0.44 foci/cell) (Figure 4). 
 No isoform-specific antibody is commercially available for MYO10, but the two major 
isoforms are distinct enough in size (hMYO10 = 165 kDa, full = 240 kDa) to distinguish by 
western blot.  The 6 cell lines (1 normal, 5 cancer) and the two patient PDAC samples tested all 
expressed hMYO10.  2 of the 5 cancer lines additionally expressed fMYO10.  Interestingly, 
Panc8.13  expressed a truncated isoform consistent with the known MYO10 frameshift insertion 
mutation in this cell lines17. 
Functional role of fMYO10 in cell lines 
 To determine the functional impact of the specific MYO10 isoforms in pancreatic cancer 
cells, we treated MiaPaCa2 cells with shRNA constructs targeting isoform-specific regions of the 
gene.  Expression of fMYO10 was successfully inhibited in MiaPaCa2 cells (Figure 6).  Previous 
studies have indicated a critical role for MYO10 in filopodia formation.  Wild type MiaPaCa2 
and fMYO10 knockout MiaPaCa2 cells were stained and imaged by fluorescent microscopy for 
differences in filopodial phenotype.  We found no qualitative difference (Figure 7A).   
 MYO10 has also been linked to invasiveness in cancer125.  We performed a wound 
healing assay on wild type and knockout cells to compare their motility.  No difference was 
observed in the rate of wound healing between these cell types (Figure 7B). 
Fusion transcripts in PanINs 
 Our fusion detection analysis was performed on the 8 samples (2 normal, and 2 from each 
PanIN grade) sequenced on the Illumina platform due to their higher read length.  Candidate 






1. Fusion event reported in normal sample 
2. Fusion event includes a gene and partnered pseudogene. 
3. Fusion partners are not in parallel or coding orientation. 
 
This reduced the list to 16 candidate fusion transcripts (Table 3), each of which was only 
detected in one PanIN sample.  The frame difference between partners of each event is included.  
It is unlikely that frame differences other than 0 produce a functional transcript, though they may 
still be real chromosomal rearrangements.  For six of these events, one or both fusion partners has 
been previously reported in human cancer, although none of them have been reported in a 
pancreatic cancer81.   These partners include: HINT1, TJP1, DNM2, LARGE, MLLT10, PP2R1B, 
and FTFT1.  A few of the partners have promising roles.  The region of DNM2 included in one 
fusion contains miRNA199-a, which is oncogenic in pancreatic cancer127.  HINT1 has been 
described as having tumor suppressor functions in certain contexts128, 129.  We detect a HINT1-
NECAP2 fusion in which HINT1 has a frameshift of 2 base pairs, possibly resulting in its 
inactivation.  NECAP2 has been recently tied to EGFR endocytosis in breast cancer130.   
 
DISCUSSION 
We identify several alternatively spliced transcripts in PanINs that may be of biological 
significance: Annexin 2 is being investigated as an antigenic target for immunotherapy 123.   
Mucins play a major part in some of the most threatening aspects of pancreatic cancer: 
therapeutic resistance, invasiveness, and metastasis131.  Mucin 1 is known to be upregulated as 
early as in low grade PanINs and has a role in tumorigenesis132.   
While two previous studies have reported oncogenic MYO10 overexpression in breast 




upregulated in PanIN3s relative to normal duct, q=0.0029), if the expression of alternate 
transcripts was not accounted for. In PanINs and in pancreatic cancer cell lines, the distribution of 
isoforms has dramatically changed from primarily hMYO10 to primarily fMYO10.    However, 
we did not observe a phenotypic difference (qualitative filopodia density or cell migration)  
between parental pancreatic cancer cells expressing fMYO10 to knockdown cells.  
Using fusion analysis, we also report on 16 in silico fusion transcripts occurring in our six 
PanIN samples that may produce chimeric mRNAs.  None of these transcripts were recurrent in 
multiple PanINs. Unfortunately, there was not sufficient RNA from these PanINs to perform a 
confirmatory RT-PCR.  Nevertheless, several of the 16 include partners previously identified as 































Figure 14. Normal duct lineage profile.  The isoform expression pattern in normal epithelium 





Figure 15. PanIN lineage profile.  The isoform expression patterns in PanIN samples matches 








Figure 16.  Alternative splicing events in PanIN3s.  Splicing events from the differential 
comparison of PanIN3s and normal duct were imported into Cytoscope and mapped with 
DomainGraph.  Each display shows differentially expressed isoforms of that gene.  The top bar is 
conserved domains and the bottom bar is exons.  Exon highlights: red = upregulated in PanIN3s, 

















Figure 17. Relative quantification of isoform-specific mRNA in pancreatic cell lines.  One 
normal pancreatic cell line (HPDE) and 3 cancer cell lines were assayed for specific isoforms of 
MUC1, ANXA2, and MYO10 by RT-PCR.  Relative isoform mRNA levels after normalization 

















Figure 18. MYO10 mRNA expression.  MYO10 is overexpressed 2.07-fold in PanIN3s 














Figure 19.  MYO10 protein isoform expression in cell lines and patient samples.   All tested 
samples are positive for the headless isoform.  MiaPaCa2 and A6 pancreatic cancer cell lines are 
positive for the full isoform.  HPNE = normal pancreatic cell line; Panc8.13, MiaPaCa2, A6, 
Panc1, and Panc10.7 = pancreatic cancer lines; PT78475 and PT77890 = primary pancreatic 

















Figure 20.  RNA in situ hybridization analysis of full MYO10 isoform expression in 
pancreatic cancer tissue.  TMAs were assayed with an isoform-specific probe for full MYO10 
mRNA.  Though both normal pancreatic ductal cells and pancreatic cancer cells express this 
















Chapter 3.  Susceptibility of ATM-















ATM is a phosphatidylinositol 3-kinase-like kinase (PIKK) that has an apical role in 
orchestrating the complex DNA damage response (DDR)133, chromatin remodeling, response to 
oxidative stress134, and other cellular functions.  Germline, biallelic inactivation of ATM  causes 
the severe,   developmental, neurodegenerative disease Ataxia Telangiectasia135, which carries a 
25% lifetime risk of cancer due to an inability to respond effectively to double-stranded breaks 
(DSBs) in DNA.  Monoallelic inactivating variants of ATM and deletion of the wild type allele 
are observed in a small percentage of familial PDAC cases, implicating ATM as a cancer 
suppressor subject to the 2-hit model 136.  Exome sequencing data of human PDAC and 
progenitor lesions has revealed Ataxia Telangiectasia Mutated (ATM) to be one of the 16 most 
commonly mutated genes in human PDAC137 and followup immunohistochemical studies have 
observed ATM protein loss in 38/347 (11%) of sporadic cancers and in 12 out of 49 (24.5%) of 
familial cancers138.  Additionally, tumoral loss of ATM was a predictor of decreased overall 
survival, suggesting ATM loss plays a very active role in cancer progression. 
The nature of this role is not yet fully clear.  Deletion of ATM in a mouse PDAC model 
has also been shown to induce epithelial-mesenchymal transition and shorter survival139.  It is 
notable that ATM is frequently inactivated by somatic mutation in other cancers and its status is a 
strong predictor for treatment outcome with DNA-damaging agents, albeit one that can cut both 
ways.  In many cases, loss of ATM sensitizes cancer cells to chemotherapeutics.  For example, 
suppression of ATM in p53 deficient MEFs sensitizes them to doxorubicin 140.  ATM-deficient 
chronic lymphocytic leukemia cells suffered a synthetic lethal effect when treated with an ATR 
inhibitor141.  In glioblastoma cells, ATM expression directly correlated with radioresistance142.  
Conversely, due to its role in triggering cell cycle arrest and apoptosis, ATM inactivation confers 
resistance to therapy in other cancers143.  High-mobility group A proteins positively regulate 




related to differences in the effects of ATM inactivation depending on p53 status: p53-deficient 
cells depend on ATM signaling for survival145 while ATM inactivation in p53-expressing cells 
confers chemoresistance140, 146.   
DDR Cascade   
DNA damage in cells is conventionally inflicted by ionizing radiation, reaction with free 
radicals, or enzymatic excision and can take the form of either single stranded breaks (SSBs) or 
DSBs.  DSBs are a dire threat to cells if left unaddressed because they can result in senescence or 
gross chromosomal rearrangements (GCRs) that give rise to cell death or cancer147.  Though less 
threatening and more easily repaired, SSBs can be compounded into DSBs by cell division or by 
two proximal lesions on opposite strands.  Cell division is also when the genome is at its most 
vulnerable to DNA damage in general and the conversion of DSBs into GCRs.  As a result of this 
and their frequent attenuation of DNA repair pathways, rapidly-dividing cancer cells are 
especially sensitive to DNA damaging agents. 
In healthy cells, ATM exists as a quiescent homodimer activated in an overlapping, 
multi-stepped process in the presence of DSBs148.  ATM is recruited to these lesions by the rapid-
response damage sensor MRE11-RAD50-NBS1 (MRN) complex, which resects the breakpoint 
ends, shedding short, single-stranded (ssDNA) oligonucleotides.  The exact mechanism and 
timing of ATM activation is a subject of some ambiguity, but it has been shown that association 
with these ssDNA oligos with or without MRN recruitment is sufficient and that their absence 
causes a rapid extinction of ATM activity149.  Conversely, it has also been shown that prolonged 
association of ATM with undamaged chromatin in the absence of ssDNA oligonucleotides can 
also trigger activation150.  Activation is marked by acetylation of lysine 3016151 and 
autophosphorylation at four sites152, causing a dissociation of the dimer to an active monomer 




recruitment153.  Upon recruitment and sustained activation, ATM associates directly with and 
phosphorylates RAD50 and NBS1154-157.  These associations are critical to the retention of ATM 
and signaling of downstream effectors with sweeping effects on the cell.   
One of the first of these effects is initiation of one of the major repair mechanisms.  The 
most common of these is classical nonhomologous end joining (C-NHEJ), in which DSBs are 
rapidly repaired by the downstream ATM targets KU70, KU86, DNA-PKcs, LIG4, XRCC4, XLF 
and Artemis147.  If rapid repair is impossible because of complications to the break or a deficiency 
in the C-NHEJ proteins, resection at the DSB ends occurs, exposing single stranded breaks 
(SSBs) that engage either homologous recombination repair (HRR) or alternative nonhomologous 
end joining (A-NHEJ)  
Especially important is ATM’s role in cell cycle arrest, which allows time to repair 
damage without compounding it through cellular division.  To this end, one of the key proteins 
phosphorylated by ATM is H2AX, which forms characteristic foci at the site of DSBs.  These 
foci recruit 53BP1 (p53), which both amplifies ATM downstream signaling and can itself be 
phosphorylated and activated by ATM158-160.  This activation is enhanced by several other 
proteins phosphorylated by ATM, including CHK2, STRAP, and HNRNPK.  ATM-
phosphorylated MDM2 conversely acts as an ubiquitin ligase on p53161, 162.  Activation of p53 
induces transcription of several genes that trigger cell cycle arrest such as p21163 as do ATM-
phosphorylated CHK1 and CHK2164, 165.  Context-dependent modulation of activated p53 and its 
downstream signals can alternatively push the cell into senescence, autophagy, or apoptosis if 
breaks cannot be efficiently repaired.   
The overarching scope of ATM’s role in the DDR and other pathways has been 
repeatedly expanded.  Proteomic screens have identified over 700 proteins bearing one or more 




reaching implications that pausing the cell cycle has for routine operations in the cell, and it is 
thought that ATM activation modulates many aspects cellular metabolism, DNA transcription, 
and protein synthesis167, 168.   
Redundancy in DDR Pathways 
The importance of DNA repair to cells necessitates redundancy in its response, and much 
of the damage can be repaired even in the absence of ATM.  Ataxia telangiectasia and Rad3-
related (ATR) is another member of the PIKK kinase family that responds to a broader range of 
DNA damage than ATM, including stalled replication forks and pyrimidine dimers in addition to 
DSBs169.   ATR recruitment and activation is dependent on the association of ATR interacting 
protein (ATRIP) and replication protein A (RPA) at a single-stranded DNA (ssDNA) locus170.  
RPA-ssDNA is a common intermediate produced by stalled replication forks, resection at DSB 
ends, and nucleotide excision repair (NER)171.  Once activated, ATR phosphorylates many of the 
same targets as ATM regulating repair, cell cycle checkpoints, and apoptosis.  Additionally, ATR 
is capable of stabilizing and restarting stalled replication forks. This property makes ATR 
indispensable to the survival of proliferating cells.  
The DNA-dependent protein kinase (DNA-PK) is another key PIKK player in DNA 
repair pathways.   The catalytic subunit of DNA-PK, DNA-PKcs, responds to DSBs, 
phosphorylating many of the same targets as ATM and ATR.  DNA-PKcs phosphorylates 
residues of polo-like kinase (PLK1), H2AX, and CHK2 that respond specifically to errors in 
mitosis.  Deletion or inhibition of DNA-PKcs leads to abnormal nuclear morphologies resulting 
from misaligned mitotic chromosomes during segregation172.  In lieu of ATM function, both ATR 
and DNA-PKcs are capable of repairing many of the DSBs that might otherwise prove intolerable 





The broad redundancies in DDR signaling are somewhat paradoxical given the severity 
of the A-T disease.  The reason for this is that while the vast majority of DSBs can be repaired by 
ATM, ATR, or DNA-PKcs somewhat interchangeably, a small subset are truly ATM-dependent.  
Observing DNA repair kinetics, Riballo et al. showed that most DSBs are repaired within 4 
hours, but approximately 10% of ‘higher complexity’ DSBs require up to 24 hours173.  ATM-
deficient cells were exclusively deficient in the latter, and in experiments they were retained as 
long as 14 days later.  Repair of these breaks required both the sustained cell cycle arrest of 
functional ATM and greater processing of breakpoint ends.  More recently, it has been shown that  
ATM-dependent DSBs occur in areas that are stoichiometrically difficult for repair complexes to 
access; because they either consist of several DSBs in close proximity or they occur in regions 
where DNA binding elements and chromatin condensation block out other proteins, such as 
heterochromatin174 and telomere-adjacent regions175.  ATM is capable of inducing chromatin 
relaxation through histone modifications such as monoubiquitylation of H2B176 and 
hyperacetylation of H4177. 
Other experiments of the Riballo et al. study showed that radiation, at doses causing the 
same number of DSBs as etoposide, caused a greater proportion of high complexity, ATM-
dependent DSBs173.  It is possible that the same circumstances that make these breaks difficult for 
repair proteins to reach are also often inaccessible to chemical agents, but not radiation.  A key 
and characteristic aspect of A-T disease is acute radiosensitivity. 
We examine the functional impact of ATM depletion on pancreatic cancer cells.  We test 
ATM-deficient cells for increased sensitivity to a variety of chemotherapeutic agents and 






MATERIALS AND METHODS 
shRNA inhibition of ATM 
 Hairpin shRNA sequences targeting ATM were designed with the Oligoengine software 







 Sequences were annealed and ligated into linearized pSuper.retro.puro vector provided by 
Salvador Suarez Naranjo in the lab of Dr. Christine Iacobuzio-Donahue.  Subcloning Efficiency 
DH5α Competent Cells (ThermoFisher) were transformed with constructs and selected with 100 
µg/ml ampicillin LB agar plates.  Isolated bacteria were grown overnight in liquid LB broth with 
100 µg/ml ampicillin and processed for plasmid using a GeneJET Plasmid Miniprep Kit 
(ThermoFisher).  Harvested plasmid was checked for correct insertion by Sanger sequencing (5’- 
GGAAGCCTTGGCTTTTG).   
 1.5 µg of pSuper construct and 1 µg of amphotropic envelope expression vector (pVSV-
G) were used to transfect GP-293 cells (ATCC) in 6-well dishes using Lipofectamine 2000 (Life 
Technologies) according to the manufacturer’s protocol.  Medium was changed after 24 hours.  
After an additional 24 hours, cell culture supernatants were harvested, filtered with 0.22 µm 
filters, and diluted 1:2 in fresh medium.  Polybrene was added to diluted viral supernatant at 6 




media was replaced with fresh media.  After an additional 48 hours, media was replaced with 
fresh media containing Puromycin Selection continued for 7 days. 
Western Blot 
Total protein lysates were extracted in RIPA buffer (Roche Diagnostics, Indianapolis, IN) 
with cOmplete Mini tablets (Roche Diagnostics) and homogenized with a Bioruptor (Diagenode, 
Denville, NJ) for 8 cycles (30s high, 30S off).   Protein concentrations were determined using the 
Pierce BCA Protein Assay Kit (ThermoScientific, Waltham, MA).  Membranes were incubated 
overnight at 4º C with primary antibodies: rabbit anti-ATM (Abcam, Cambridge, MA) or goat 
anti-Actin (Santa Cruz Biotechnology).  Membranes were incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibody in 5% dry milk for 1 hour.  Bound antibody was detected 
with a Pierce ECL Plus kit (ThermoScientific). 
Chemosensitivity 
 Chemosensitivity assays were performed using a protocol previously described178.  In 
brief, cells were plated at a density of 3,000 cells/well in the 60 center wells of 96-well plates.  
Edge wells were filled with PBS.  Media was aspirated 24 hours later and replaced with 200 
ul/well drug-supplemented media.  Drugs were serially diluted 10-fold in standard growth 
medium at concentrations ranging from 1 nm to 100 um.  For drugs dissolved in dimethyl 
sulfoxide (DMSO) vehicle, untreated cells were incubated in DMSO-supplemented media as a 
negative control.  Plates were incubated for 72 hours.  10% AlamarBlue Cell Viability reagent 
(ThermoFisher Scientific) was added to each well as per the manufacturer’s protocol.   Readings 
were performed using a BMG FluoStar Galaxy instrument (BMG LAbtechnologies; excitation at 
544 nm, reading at 590 nm).  Statistical analyses were performed and ic50 curves were generated 





 We utilized a protocol described by Dr. James Eshleman.  Cells were plated at low 
density (9 cells/well Panc2.5 and MiaPaCa2, 45 cells/well Panc8.13) and irradiated in a 
Gammacell 40A (cesium-137 source) at 0/2/4/6 Gy, then allowed to grow until distinct colonies 
of >50 cells were countable in untreated plates (8-21 days, depending on cell line).  For 
fractionated radiation experiments, doses were delivered every 24 hours.  Staining was performed 
with Crystal Violet solution (5% Crystal Violet, 25% methanol) and wells with 1 or more 
colonies of >50 cells were counted.  Cloning efficiency was calculated as: (-ln(total wells-clone 
wells/total wells))/(number of cells/well) normalized to the number of clone-positive wells on 
untreated plates.  
Chemoradioclonogenicity 
 Cells were plated at low density (9 cells/well) and allowed to attach overnight.  Media 
was replaced by serially-diluted drugs at 16 wells/dose: MiaPaCa2 (1 nm-10 µm Ve821 ATR 
inhibitor) and Panc2.5 (1 nm-1 µm Nu7441 DNA-PKcs inhibitor).  Plates were irradiated in a 
Gammacell 40A at 0/1/2/4/6 Gy (MiaPaca2) and 0/2/4 Gy (Panc2.5).  After 14 days, staining was 
performed with Crystal Violet solution and wells with 1 or more colonies of >50 cells were 
counted.  Cloning efficiency was calculated as previously. 
Comet Assay 
 Comet assay was performed with a protocol provided by Dr. Mohammad Hedeyati.  Cells 
were detached and resuspended in 5 ml media at 2 x 105 cells/ml stored on ice to minimize DNA 
damage from handling.  CometAssay LMAgarose (Trevigen, Gaithersburg, MD) was kept ready 
in a 37º water bath. On ice, cells were irradiated in a Gammacell 40A at 4 Gy. 
 50 µl of cells were combined with 400 µl of LMAgarose and gently mixed.  50 µl of mix 
was added to each well of a Flare Slide (Trevigen) and spread evenly with a pipet tip.  Slides 




glass dish filled with CometAssay Lysis Solution (Trevigen) for 1 hour at 4º C.  Slides were 
washed twice for 15 min in TBE solution and electrophoresed for 40 minutes at 4º C in TBE 
buffer using 1 V/cm length of the box.  DNA was stained with DAPI ProLong Gold Antifade 
Mountant (ThermoFisher Scientific) and imaged on a Confocal Eclipse Ti-E microscope (Nikon 
Instruments, San Quirico, Italy).  Pictures were taken of 100 cells for each sample and analyzed 
with CometAssay software (www.autocomet.com). 
RESULTS 
Inhibition of ATM 
   In order to understand the role played by ATM in pancreatic cancer cells, we knocked 
down expression of ATM in two cell lines expressing mutant p53 (MiaPaCa-2, Panc2.5) and one 
cell line expressing wild type p53 (Panc8.13) using shRNA constructs targeting ATM. (Figure 1).    
Chemosensitivity 
 We treated our ATM-deficient cells with serial dilutions of a variety of chemotherapeutic 
agents and measured their viability.  We focused primarily on DNA-damaging agents, including 
gemcitabine, olaparib, cisplatin, topotecan, doxorubicin, and mitomycin c.  We also examined 
agents inhibiting other DNA repair factors in the hopes of exploiting synthetic lethality including 
Ve821 (ATR inhibitor) and Nu7441 (DNA-Pkcs inhibitor).   
 Although most of these agents inflicted substantial mortality on all of the tested lines, we 
observed no difference in the chemosensitivity of ATM-deficient cells vs. ATM wild type cells 
(Figure 2).  We conclude that ATM-deficient pancreatic cancer cells do not have increased 





 It has long been known that patients with ATM are exceptionally sensitive to DNA 
damage induced by radiation. Although ATM deficiency might be expected to induce 
radiosenstivity in pancreatic cancer cells, pancreatic cancer is a relatively radioresistant cancer 
and it is known if ATM deficiency would render pancreatic cancer cells radiosensitive.  We 
sought to determine if our ATM-deficient PDAC cells exhibited this effect by calculating the 
cloning efficiency of irradiated cells.   Panc2.5, MiaPaCa-2, and Panc8.13 lines showed markedly 
reduced cloning efficiency at all radiation doses in ATM-deficient cells compared to ATM wild 
type cells (Figure 3).  In all three lines, the difference in cloning efficiency between ATM-
deficient and wild type cells grew with each radiation dose.  While surviving wild type clones 
generally appeared healthy and stable at lower doses, surviving ATM-deficient cells at any dose 
frequently exhibited aberrations: cell enlargement, multinucleation, and twisted, malformed cell 
boundaries.  Such changes are known to be markers of cells enduring sustained genotoxic 
insult179. 
 It is possible that many ATM-deficient cells were able to survive irradiation by repairing 
DSBs with compensatory DNA repair mechanisms such as ATR and DNA-PKcs.  We repeated 
our radioclonogenicity assays on MiaPaCa2 with simultaneous application of an ATR inhibitor 
and on Panc2.5 with a DNA-PKcs inhibitor.  In each case, we saw no multiplicative impact on 
cloning efficiency of ATM-deficient cells that would suggest a synergistic interaction of the 
agents (Figure 4). 
 Another strategy to improve radiosensitivity of cancer cells is to fractionate large doses 
of radiation into several smaller doses.  The sensitivity of DNA to radiation damage varies across 
the cell cycle, with greater vulnerability during G2 and M phases and greater resistance during the 
S phase180.  By delivering multiple doses of radiation at different timepoints, different fractions of 
rapidly-dividing cancer cells may be caught during their more sensitive phases.  Additionally, 




As peripheral, sensitive cells are killed by early doses, oxygen is able to reach internal cells, 
sensitizing them in turn to successive doses.  Fractionated radiation is also appealing because it is 
less toxic for the patient than a single, high dose.  The lower amounts of DNA damage inflicted 
by lighter exposures can be tolerated and repaired by normal cells in-between doses.  Cancer cells 
that have their DNA repair mechanisms attenuated may be unable to repair even small amounts of 
damage efficiently, allowing repeated doses to have a compounding effect that results in halted 
replication and apoptosis. 
 We applied fractionated radiation doses to ATM-inhibited Panc2.5 and Panc8.13 cells.  
Cells were treated with either 5 Gy or a therapeutically equivalent 6 Gy over 3 doses of 2 Gy 
each.  We find that in both lines, the fractionated doses were marginally more effective at 
inhibiting clonogenic growth than the single 5 Gy dose against ATM-deficient, but not ATM wild 
type cells (Figure 23).   
 We were additionally interested in whether any synergistic effect could be observed 
between treatment with olaparib, a PARP inhibitor, and fractionated radiation.  We repeated our 
fractionated radioclonogenicity assay on Panc2.5 and Panc8.13 cells, treating cells with 100 nm 
Olaparaib 1 hour before each radiation dose.  In both cell lines, we observed total loss of 
clonogenicity in ATM-inhibited cells that were treated with olaparib or DMSO (control) and 3 
doses of 2 Gy radiation.  We additionally observed a total loss of clonogenicity in Panc8.13 ATM 
wild type cells treated with olaparib and 3 doses of 2 Gy radiation. 
DNA Damage 
 Several assays exist to assess DNA damage by imaging and quantifying foci of response 
factors such as H2AX, but given ATM’s apical role in recruiting many of these factors to DSBs, 
we resolved to examine the DNA of cells directly.  In the comet assay, treated cells are embedded 




Electrophoresis of the nucleoids results in a ‘tail’ of broken DNA fragments extruding that 
resembles a comet.  By staining the DNA and measuring the proportional intensity of radiation in 
the head and tail of the comet, we can determine the extent of DNA damage that has occurred. 
 Treating MiaPaCa-2 cells with 4 Gy radiation, we observe a reduced fraction of DNA in 
the comet head of cells immediately post-exposure (Figure 25A).  This loss was equal between 
wild type and ATM-deficient cells, reflecting no difference in the amount of DNA damage 
inflicted.  This was unsurprising as ATM should not affect the rate at which DNA damage occurs 
in the cell, but rather its ability to tolerate and repair that damage. 
 With that in mind, we next used the comet assay to quantify the repair kinetics of 
MiaPaCa-2, Panc2.5, and Panc8.13 cells in the hours post-exposure to 4 Gy radiation.  In all three 
lines, we observed comparable DNA damage in wild type and ATM-deficient cells immediately 
post-exposure.  This was followed by a small but significant difference in the amount of DNA 
repaired at later timepoints between wild type and ATM-deficient cells: Panc8.13, 11% at 14 
hours (p-value = 1.45732 x 10-11) (Figure 25B); MiaPaCa-2, 14% at 24 hours (p-value = 0.00006) 
(Figure 25C); Panc2.5, 8% at 48 hours (p-value = 0.00006) (Figure 25D).  This result is highly 
consistent with past findings that the repair of 10-15% of DSBs is ATM-dependent173. 
DISCUSSION 
 Much recent attention in cancer has been devoted to the concept of targeted therapy: a 
strategy of matching treatments to the specific genetic landscape of a patient’s disease.  Because 
pancreatic cancer has proven particularly resistant to non-surgical interventions, identification of 
markers for cancers excepted from this rule would be very valuable.  Next generation sequencing 
(NGS) is enabling the detection of mutations in pancreatic cancers in the clinic. And  in a recent 
study, an ATM mutation was detectable by targeted NGS in endoscopic ultrasound fine needle 




Interestingly, we were unable to identify differential chemosensitivity of pancreatic 
cancer cells with ATM-deficient cells compared to parental cells with intact ATM. This was the 
case for the Parp inhibitor, olaparib: in vitro studies 182 and clinical trials  have found PARP 
inhibitors such as olaparib to be especially effective in ATM-deficient breast and prostate 
cancers183, 184.  
   In all three lines tested, ATM-deficient PDAC showed a marked loss of ability to form 
proliferative colonies post-irradiation in comparison to PDAC cells expressing wild type 
ATM.We also assayed DNA repair kinetics for irradiated cells.  We determined that in ATM-
deficient PDAC cells, ~10% more DSBs are retained at 48 hours than in ATM wild type cells.  
Our study supports the hypothesis that ATM-deficient pancreatic cancers are radiosensitive. Our 


































Figure 22.  Chemosensitivity of ATM-deficient pancreatic cancer cell lines.   Cells were 
exposed to serial dilutions of each agent from 1 nm to 100 um for three days, then assayed for 
viability with AlamarBlue.   Ic50 values were calculated from the  dose-response curve. Mia-
PaCa2 and Panc2.5 cells deficient in ATM did not show any increased sensitivity to 

















Figure 23.  Radiosensitivity of ATM-deficient pancreatic cancer cell lines.   Cells were plated 
at 96 wells and irradiated.  After 14-21 days, positive wells were counted as those with one or 
more colonies of >50 cells, cloning efficiencies were calculated for each condition, and 
normalized to the untreated cells of each cell line.  In all three lines tested, ATM inhibition 














Figure 24. Chemoradioclonogenicity of ATM-deficient cells. Cells were plated at 96 wells and 
treated with Ve821 ATR inhibitor (MIA PaCa-2 cells, A, B) or Nu7441 DNA-PKcs inhibitor 
(Panc2.5 cells, C, D) one hour before irradiation.  After 14-21 days, positive wells were counted 
as those with one or more colonies of >50 cells, cloning efficiencies were calculated for each 
condition, and normalized to the untreated cells of each cell line.  There was no synergistic effect 















Figure 25.  Cells were plated on 96-well plates and irradiated.  Fractionated radiotherapy 
doses were applied every 24 hours.  CE values were calculated from the number of wells out of 
96 containing clones of 50 or more cells for each treatment.   CE values were normalized to the 
CE values of each untreated cell line.  ATM-deficient cells in both cell lines were slightly more 
















Figure 26. Combination therapy of Olaparaib and fractionated radiation.  Cells were plated 
on 96-well plates.  Every 24 hours, media was replaced with normal media + 100 nm Olaparib or 
normal media + 0.1% DMSO.  Fractionated radiotherapy doses were applied one hour after 
changing media.  CE values were calculated from the number of wells out of 96 containing clones 
of 50 or more cells for each treatment.   CE values were normalized to the CE values of each 
untreated cell line.  ATM-deficient cells in both cell lines were slightly more sensitive to 













Figure 27.  DNA repair kinetics of ATM-deficient cells.  The comet assay was used to evaluate 
DNA damage in cells post-irradiation.  For each condition, 100 cells were imaged and analyzed 
for the proportion of DNA in their head (intact) and tail (damaged).   A) Immediately post-
irradiation, there is no significant difference in the proportion of damaged DNA between ATM-
deficient and wild type cells.  B-D) The comet assay was performed on cells at multiple 
timepoints post-irradiation.  In all three cell types,  the percentage of DNA in comet heads was 
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